View clinical trials related to Presbyopia.
Filter by:Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNZ101 and LNZ100 Ophthalmic Solutions in Chinese Healthy Adult Subjects with Presbyopia
This is a single-center, open-label, randomized study to assess the plasma pharmacokinetic profile of LNZ101 and LNZ100.
The study objective was to gather short-term clinical performance data for two soft multifocal contact lenses.
The objective of the study is to compare the lens performance of two daily disposable multifocal contact lenses.
The purpose of this study is to evaluate the long-term safety of the IC-8 Apthera intraocular lens (IOL).
Safety Study of the Long-Term Safety of LNZ101 in Presbyopic Subjects
The clinical investigation objective is to evaluate safety and performance outcomes of trifocal IOL implantation to improve vision in patients with cataract and/or ametropia (hyperopia, myopia) and/or presbyopia. Retrospective data from preoperative status up to 12 month postoperative status will be collected from patients that were implanted with Medicontur's 640PM intraocular lens: - Preoperative status: Preoperative Screening and Baseline - Surgery: IOL implantation - M1: 1 month +/- 2 weeks postoperative follow-up - M3: 3 months +/- 1 month postoperative follow-up - M12: 12 months +/- 3 months postoperative follow-up
The purpose of this study was to compare the clinical performance of two fitting approaches for multifocal contact lenses.
Phase 3 Efficacy Study to evaluate the Safety and Efficacy of LNZ101 for the Treatment of Presbyopia
The purpose of this clinical trial is to assess the clinical performance of LID223194 Multifocal (MF) contact lenses and commercially available Air Optix plus HydraGlyde (AOHG) MF contact lenses. Eligible subjects will wear each study lens type in a cross-over fashion as randomized for approximately 2 days.